课题基金 / 基金详情

FACSVantage SE Upgrade

FACSVantage SE Upgrade
FACSVantage SE 升级
批准号:
6731842
负责人:
RAYMOND B HESTER
金额:
$22.64万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-01 至 2005-03-31

项目摘要

项目成果

RAYMOND B HESTER的其他基金

相关文献

中文摘要
翻译
描述(由申请人提供):该提案,如果获得资助,将使我们的Becton Dickinson facadvantage SE流式细胞仪升级为包括DiVa电子,TurboSort和更换15年旧激光器成为可能。本申请中包含的项目是由南阿拉巴马大学(美国)医学院(COM)五个系的教师进行的,包括微生物学/免疫学、生物化学和分子生物学、细胞生物学和神经科学、药理学和医学系,以及美国癌症研究所、肺生物学中心和镰状细胞中心。其中9个项目涉及美国国立卫生研究院资助的研究人员。这一升级所代表的技术和可靠性在以下领域的研究是必需的:1)环境因子诱导的DNA修复,2)未成熟层粘连蛋白受体蛋白(iLRP)在肿瘤发生和免疫细胞活化中的作用,3)前列腺上皮细胞特异性基因调控,4)丝氨酸/苏氨酸蛋白磷酸酶对细胞周期进程的调控,5)抗体介导的疱疹基质角膜炎保护和趋化因子在角膜炎症中的作用,6)新世界灵长类动物淋巴细胞信号转导,7)转移相关抗原在人癌细胞上的表达及肿瘤细胞对治疗的敏感性机制,8)遗传性线粒体疾病的逆转,NARP(神经病变、心性失调、色素性视网膜炎)和MILS(母系遗传性利氏综合征),9)鸟氨酸脱羧酶在内皮细胞毒素、单罗塔碱中的作用,10)活化的白细胞粘附分子和活化的单核细胞在急性胸痛发病中的作用,11)红细胞内皮细胞粘附在镰状细胞病急性肺损伤中的作用,12)骨软骨组织移植中的时体细胞活力,13)镰状细胞病急性肺损伤及红细胞内皮细胞粘附的作用,14)人癌细胞转移相关抗原表达的研究,15)癌症患者免疫治疗的研究。美国国立卫生研究院资助的研究人员越来越意识到,要求排序速度比我们现在配置的Vantage SE更快。此外,1988年与我们的FACS 440购买的激光器,并于1998年转移到Vantage SE,随着维修变得越来越昂贵和零件稀缺,它们的使用寿命即将结束。通过消除电子死区时间,四向排序(和增加)排序产量,采集后补偿,在信号触发方面具有更大的灵活性,以及更好的数据分辨率,这些都是DiVa选项的功能,将使我们用户组的所有成员受益。
英文摘要
DESCRIPTION (provided by applicant): This proposal, if funded, will make possible an upgrade of our Becton Dickinson FACSVantage SE flow cytometer to include DiVa electronics, TurboSort, and the replacement of fifteen-year old lasers. The projects included in this application are being conducted with faculty in five departments within the University of South Alabama (USA) College of Medicine (COM) including the Departments of Microbiology/Immunology, Biochemistry and Molecular Biology, Cell Biology and Neuroscience, Pharmacology and Medicine, as well as the USA Cancer Research Institute, the Center for Lung Biology and the Sickle Cell Center. Nine of the projects involve NIH-funded investigators. The technology and reliability represented by this upgrade are required in the following areas of research in the USA COM: 1) repair of DNA induced by environmental agents, 2) the role of immature laminin receptor protein (iLRP) in tumor development and immune cell activation, 3) prostate epithelial cell-specific gene regulation, 4) regulation of cell cycle progression by ser/thr protein phosphatases, 5) antibody-mediated protection against herpes stromal keratitis and the role of chemokines in corneal inflammation, 6) cellular signaling in lymphocytes from New World primates, 7) metastasis-related antigen expression on human cancer cells and mechanisms of tumor cell sensitivity to therapy, 8) the reversal of inheritable mitochondrial disorders, NARP (neuropathy, ataxia, retinitis pigmentosa) and MILS (maternally inherited Leigh Syndrome), 9) role of ornithine decarboxylase in the endothelial cell toxin, monocrotaline, 10) role of activated leukocyte cell adhesion molecule and activated monocytes in the pathogenesis of acute chest pain, 11) role of erythrocyte-endothelial cell adhesion in acute lung injury in sickle cell disease, 12) chrondrocyte viability in osteochondrial tissue transfer, 13) acute lung injury in sickle cell disease and the role of erythrocyte-endothelial cell adhesion, 14) studies on metastasis-related antigen expression on human cancer cells, and 15) studies in immunotherapy in cancer patients. There has been an increasing awareness on the part of our NIH-funded investigators to require sort rates faster than those available with our Vantage SE as it is now configured. In addition, the lasers purchased with our FACS 440 in 1988, and transferred to the Vantage SE in 1998, are approaching the end of their useful lifespan as repairs becoming increasingly expensive and parts scarce. Four-way sorting (and increased) sort yields through the elimination of electronic dead-time), post acquisition compensation, greater flexibility with regard to signal triggering, and better data resolution, which are features of the DiVa option, will benefit all the members of our user group.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FACSVANTAGE SE UPGRADE: LUNG
  • 批准号:
    6973359
  • 项目类别:
  • 资助金额:
    $3.96万
  • 财政年份:
    2004
  • 负责人:
    RAYMOND B HESTER
  • 依托单位:
FACSVANTAGE SE UPGRADE: ENVIRONMENTAL HEALTH
  • 批准号:
    6973361
  • 项目类别:
  • 资助金额:
    $1.13万
  • 财政年份:
    2004
  • 负责人:
    RAYMOND B HESTER
  • 依托单位:
FACSVANTAGE SE UPGRADE: CANCER
  • 批准号:
    6973358
  • 项目类别:
  • 资助金额:
    $8.49万
  • 财政年份:
    2004
  • 负责人:
    RAYMOND B HESTER
  • 依托单位:
FACSVANTAGE SE UPGRADE: EYE
  • 批准号:
    6973360
  • 项目类别:
  • 资助金额:
    $1.13万
  • 财政年份:
    2004
  • 负责人:
    RAYMOND B HESTER
  • 依托单位: